LEO 90105 Ointment in Japanese Subjects With Psoriasis

Model scores of the 29,894 trials active now.

Model score 4% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (238 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: diseaseivhearttherapyiii or
  Phrases that lowered it: psoriasisvulgaristopicalareaacne
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 9.4% (raises risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Minimum age: 20 (lowers risk) · Who can join
• Drug's FAERS reports with a death: 7.2% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 27 (lowers risk) · Sponsor's track record
• Blinding: quadruple (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Keywords listed: 9 (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area
• Sponsor's past trials: 53 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris NCT00764751 · started 2008 · scored riskier than 6% of active trials completed
• Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris NCT00670241 · started 2008 · scored riskier than 3% of active trials completed
• The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris NCT01768013 · started 2012 · scored riskier than 4% of active trials completed
• An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris NCT01466478 · started 2011 · scored riskier than 3% of active trials completed
• LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris NCT01536886 · started 2012 · scored riskier than 6% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.